Introduction: Migraine is a highly prevalent and disabling neurological condition whose personal, social and economic impact is substantial. Abortive and preventative treatments of this condition are still unsatisfactory, with poor control of the acute symptoms of the single attacks in many cases and a frequent progression towards chronicity. Areas covered: The major drug classes recently developed and/or in current development for migraine treatment are discussed. These include: Calcitonin-Gene-Related Peptide (CGRP) receptor antagonists, mAbs against CGRP or its receptor, selective 5 hydroxytryptamine (5-HT)1F receptor agonists, drugs targeting Acid-Sensing Ion Channels, Transient Receptor Potential channels and Nitric Oxide. Expert opinion: The most convincing results appear those obtained with mAbs against CGRP, particularly in migraine preventative treatment, given the absence of serious adverse events, and the good response in terms of pain relief. If these results are confirmed in larger studies, these compounds have the potential to significantly improve the pharmacological control of migraine and also its evolution towards chronicity.

Emerging drugs for migraine treatment / M. A., Giamberardino; Martelletti, Paolo. - In: EXPERT OPINION ON EMERGING DRUGS. - ISSN 1472-8214. - STAMPA. - 20:1(2015), pp. 1-11. [10.1517/14728214.2015.999040]

Emerging drugs for migraine treatment

MARTELLETTI, Paolo
2015

Abstract

Introduction: Migraine is a highly prevalent and disabling neurological condition whose personal, social and economic impact is substantial. Abortive and preventative treatments of this condition are still unsatisfactory, with poor control of the acute symptoms of the single attacks in many cases and a frequent progression towards chronicity. Areas covered: The major drug classes recently developed and/or in current development for migraine treatment are discussed. These include: Calcitonin-Gene-Related Peptide (CGRP) receptor antagonists, mAbs against CGRP or its receptor, selective 5 hydroxytryptamine (5-HT)1F receptor agonists, drugs targeting Acid-Sensing Ion Channels, Transient Receptor Potential channels and Nitric Oxide. Expert opinion: The most convincing results appear those obtained with mAbs against CGRP, particularly in migraine preventative treatment, given the absence of serious adverse events, and the good response in terms of pain relief. If these results are confirmed in larger studies, these compounds have the potential to significantly improve the pharmacological control of migraine and also its evolution towards chronicity.
2015
acid-sensing ion channels; acute and preventative treatment; antibodies against CGRP; CGRP receptor antagonists; migraine, nitric oxide; 5 hydroxytryptamine1F; transient receptor potential channels
01 Pubblicazione su rivista::01a Articolo in rivista
Emerging drugs for migraine treatment / M. A., Giamberardino; Martelletti, Paolo. - In: EXPERT OPINION ON EMERGING DRUGS. - ISSN 1472-8214. - STAMPA. - 20:1(2015), pp. 1-11. [10.1517/14728214.2015.999040]
File allegati a questo prodotto
File Dimensione Formato  
Giamberardino_Emerging_2014.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 295.61 kB
Formato Adobe PDF
295.61 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/781940
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 31
social impact